A PHASE 1B TRIAL OF HU5F9-G4 MONOTHERAPY OR HU5F9-G4 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Protocol: 
AAAR4923
Phase: 
I

A PHASE 1B TRIAL OF HU5F9-G4 MONOTHERAPY OR HU5F9-G4 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Are you Eligible? (Inclusion Criteria)

1) Subject must be at least 18 years of age.
2) Subjects must have confirmed Relapsed/Refractory AML, MDS, or previously untreated AML.
3) Subjects must be able to understand and willingly sign a written informed consent form.

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States